Drug Trial Radar · NCT02506153
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,301
Actual
Start
Nov 10, 2015
Primary completion
Sep 15, 2023
Study completion Jan 23, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether pembrolizumab is more effective than the current standard of care in treating patients with melanoma.
Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Cutaneous Melanoma
- Metastatic Mucosal Melanoma
- Metastatic Non-Cutaneous Melanoma
- Non-Cutaneous Melanoma
- Recurrent Cutaneous Melanoma
- Recurrent Mucosal Melanoma
- Recurrent Non-Cutaneous Melanoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
PembrolizumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET scan
Quality-of-Life AssessmentOther
Ancillary studies
Recombinant Interferon Alfa-2bBiological
Given IV and SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: 5 years after last randomization
Locations
576 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Cancer Center at Saint Joseph's
Phoenix, Arizona
Virginia G Piper Cancer Care-Del Camino
Scottsdale, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Highlands Oncology Group - Rogers
Rogers, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Sutter Auburn Faith Hospital
Auburn, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California
Sutter Cancer Research Consortium
Novato, California
Kaiser Permanente-Oakland
Oakland, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Kaiser Permanente - Panorama City
Panorama City, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Showing 40 of 576 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.